XOMA Royalty (XOMA) Non-Current Assets (2010 - 2026)
XOMA Royalty (XOMA) reported Non-Current Assets of $153.1 million for Q1 2026, up 53.84% on a YoY basis from $99.5 million in Q1 2025, and down 1.5% sequentially from $155.4 million in Q4 2025.
XOMA Royalty (XOMA) Non-Current Assets (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Non-Current Assets data on file, last reported at $153.1 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 53.84% year-over-year to $153.1 million; the trailing twelve-month figure through Mar 2026 stood at $526.6 million (up 54.61% YoY), and the FY2025 full-year result was $155.4 million, up 62.47% from the prior year.
- Non-Current Assets eased to $153.1 million in Q1 2026, from $155.4 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $155.4 million in Q4 2025 to a low of $64.3 million in Q3 2024.
- A 5-year average of $90.8 million and a median of $84.2 million in 2023 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets declined 28.21% in 2024 and jumped 62.47% in 2025, its largest moves.
- Tracing XOMA's Non-Current Assets over 5 years: stood at $79.1 million in 2022, then decreased by 17.87% to $65.0 million in 2023, then jumped by 47.22% to $95.7 million in 2024, then jumped by 62.47% to $155.4 million in 2025, then declined by 1.5% to $153.1 million in 2026.
- Business Quant data shows XOMA's Non-Current Assets at $153.1 million in Q1 2026, $155.4 million in Q4 2025, and $118.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 153.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153.11 Mn |
| Dec 31, 2025 | 155.44 Mn |
| Jun 30, 2025 | 118.53 Mn |
| Mar 31, 2025 | 99.53 Mn |
| Dec 31, 2024 | 95.67 Mn |
| Sep 30, 2024 | 64.32 Mn |
| Jun 30, 2024 | 81.08 Mn |
| Mar 31, 2024 | 72.53 Mn |
| Dec 31, 2023 | 64.99 Mn |
| Sep 30, 2023 | 89.59 Mn |
| Jun 30, 2023 | 87.24 Mn |
| Mar 31, 2023 | 88.59 Mn |
| Dec 31, 2022 | 79.13 Mn |
| Sep 30, 2022 | 66.39 Mn |
| Jun 30, 2022 | 66.96 Mn |
| Mar 31, 2022 | 69.55 Mn |
| Dec 31, 2021 | 69.59 Mn |
| Sep 30, 2021 | 55.63 Mn |
| Jun 30, 2021 | 48.50 Mn |
| Mar 31, 2021 | 49.65 Mn |